THRIVENT FINANCIAL FOR LUTHERANS - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
THRIVENT FINANCIAL FOR LUTHERANS ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$18
-14.3%
15,0000.0%0.00%
Q2 2023$21
-4.5%
15,0000.0%0.00%
Q1 2023$22
+22.2%
15,0000.0%0.00%
Q4 2022$18
-99.9%
15,0000.0%0.00%
Q3 2022$17,000
-84.1%
15,000
-64.7%
0.00%
Q3 2021$107,000
-11.6%
42,533
-0.3%
0.00%
Q2 2021$121,00042,6700.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders